81 related articles for article (PubMed ID: 10697552)
1. Immunological properties of tumor cells genetically modified to secrete interleukin-2.
Takashima I; Yamaguchi Y; Yorishima T; Ohta K; Minami K; Hihara J; Toge T
Anticancer Res; 1999; 19(6B):5299-306. PubMed ID: 10697552
[TBL] [Abstract][Full Text] [Related]
2. Co-transduction of herpes simplex virus thymidine kinase gene and human interleukin-2 gene into mouse ovarian cancer cell line, OVHM.
Yamaguchi Y; Takashima I; Hihara J; Ohta K; Shimizu K; Minami K; Yoshida K; Toge T
Int J Mol Med; 2000 Aug; 6(2):185-90. PubMed ID: 10891564
[TBL] [Abstract][Full Text] [Related]
3. [Effects of IL-18 gene transfection on the proliferation in vitro and tumorigenesis in vivo of mouse ovarian cancer cell line OVHM].
Cui C; Hao SW; Li XW; Bai XJ; Cheng JX; Shan BE
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Jun; 24(6):577-80. PubMed ID: 18538088
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo characteristics of human squamous cell carcinoma of the head and neck cells engineered to secrete interleukin-2.
Nagashima S; Reichert TE; Kashii Y; Suminami Y; Chikamatsu K; Whiteside TL
Cancer Gene Ther; 1997; 4(6):366-76. PubMed ID: 9408607
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of established pancreatic cancers following specific active immunotherapy with interleukin-2 gene-transduced tumor cells.
Clary BM; Coveney EC; Philip R; Blazer DG; Morse M; Gilboa E; Lyerly HK
Cancer Gene Ther; 1997; 4(2):97-104. PubMed ID: 9080118
[TBL] [Abstract][Full Text] [Related]
6. Functional and molecular characterization of interleukin-2 transgenic Ewing tumor cells for in vivo immunotherapy.
Staege MS; Hansen G; Baersch G; Burdach S
Pediatr Blood Cancer; 2004 Jul; 43(1):23-34. PubMed ID: 15170886
[TBL] [Abstract][Full Text] [Related]
7. Generation of cytotoxic effector lymphocytes by MLTC using tumor cells genetically modified to secrete interleukin-2.
Yamaguchi Y; Ohta K; Shimizu K; Minami K; Noma K; Hihara J; Toge T
Anticancer Res; 2001; 21(1B):669-77. PubMed ID: 11299824
[TBL] [Abstract][Full Text] [Related]
8. [Effects of interleukin-12 transfection on proliferation of ovarian cancer SKOV3 cells in vitro and in vivo].
Wang J; Zhang CQ; Liu J; Sui LH
Ai Zheng; 2007 Dec; 26(12):1292-8. PubMed ID: 18076789
[TBL] [Abstract][Full Text] [Related]
9. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
10. Combining radiation therapy with interleukin-3 gene immunotherapy.
Chiang CS; Hong JH; Wu YC; McBride WH; Dougherty GJ
Cancer Gene Ther; 2000 Aug; 7(8):1172-8. PubMed ID: 10975678
[TBL] [Abstract][Full Text] [Related]
11. Gene therapy for murine renal cell carcinoma using genetically engineered tumor cells to secrete interleukin-12.
Kasaoka Y; Nakamoto T; Wang J; Usui T; Hamada H
Hiroshima J Med Sci; 2000 Mar; 49(1):29-35. PubMed ID: 10824454
[TBL] [Abstract][Full Text] [Related]
12. Effect of interleukin-7 gene transfection into ovarian carcinoma cell line SKOV3 in vitro and in vivo.
Xie X; Ye DF; Chen HZ; Lu WG; Fu YF; Cheng B; Zhu H
Gynecol Oncol; 2004 Feb; 92(2):578-85. PubMed ID: 14766250
[TBL] [Abstract][Full Text] [Related]
13. Secretion of interleukin-10 from murine colon carcinoma cells suppresses systemic antitumor immunity and impairs protective immunity induced against the tumors.
Kawamura K; Bahar R; Natsume W; Sakiyama S; Tagawa M
Cancer Gene Ther; 2002 Jan; 9(1):109-15. PubMed ID: 11916240
[TBL] [Abstract][Full Text] [Related]
14. A convenient cancer vaccine therapy with in vivo transfer of interleukin 12 expression plasmid using gene gun technology after priming with irradiated carcinoma cells.
Nishitani MA; Sakai T; Ishii K; Zhang M; Nakano Y; Nitta Y; Miyazaki J; Kanayama HO; Kagawa S; Himeno K
Cancer Gene Ther; 2002 Feb; 9(2):156-63. PubMed ID: 11857033
[TBL] [Abstract][Full Text] [Related]
15. [Biological and antitumor effects of CD40L on ovarian cancer cell line OVHM].
Zhang ZM; Zhang C; Zhang FH; Shan BE; Nakagawn S; Tagawa M
Ai Zheng; 2006 Sep; 25(9):1102-7. PubMed ID: 16965650
[TBL] [Abstract][Full Text] [Related]
16. Melanoma differentiation-associated gene-7 (mda-7)/interleukin (IL)-24 induces anticancer immunity in a syngeneic murine model.
Miyahara R; Banerjee S; Kawano K; Efferson C; Tsuda N; Miyahara Y; Ioannides CG; Chada S; Ramesh R
Cancer Gene Ther; 2006 Aug; 13(8):753-61. PubMed ID: 16543916
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-2 gene-transduced human leukemic cells induce major histocompatibility complex-restricted and -unrestricted anti-leukemic effectors in mixed lymphocyte-tumor cultures.
Cignetti A; Guarini A; Gillio Tos A; Reato G; Foa R
Cancer Gene Ther; 2000 Feb; 7(2):167-76. PubMed ID: 10770624
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells.
Kinoshita Y; Kono T; Yasumoto R; Kishimoto T; Wang CY; Haas GP; Nishisaka N
J Immunother; 2001; 24(3):205-11. PubMed ID: 11394497
[TBL] [Abstract][Full Text] [Related]
19. Insertion of the IL-2 gene decreases tumorigenicity of murine fibrosarcoma.
Kuśnierczyk H; Załecki P; Pajtasz-Piasecka E; Radzikowski C
Arch Immunol Ther Exp (Warsz); 1998; 46(4):259-65. PubMed ID: 9779293
[TBL] [Abstract][Full Text] [Related]
20. Impaired tumorigenicity of human pancreatic cancer cells retrovirally transduced with interleukin-12 or interleukin-15 gene.
Yoshida Y; Tasaki K; Miyauchi M; Narita M; Takenaga K; Yamamoto H; Yaaguchi T; Saisho H; Sakiyama S; Tagawa M
Cancer Gene Ther; 2000 Feb; 7(2):324-31. PubMed ID: 10770643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
